BMB Reports Papers in Press available online.

Search Papers In Press
This galley proof is being listed electronically before publishing the final manuscript (It's not final version).

6-Sialyllactose ameliorates dihydrotestosterone-induced benign prostatic hyperplasia through suppressing VEGF-mediated angiogenesis
Eun-Yeong Kim1,2,#, Bo-Ram Jin3,#, Tae-Wook Chung2, Sung-Jin Bae2, Hyerin Park1,2, Dongryeol Ryu1,2, Ling Jin1,2, Hyo-Jin An3, Kitae Ha1,2,*
1Department of Korean Medical Science, School of Korean Medicine, Pusan National University,
2Korean Medical Research Center for Healthy Aging, Pusan National University,
3Department of Pharmacology, College of Korean Medicine, Sangji University
Benign prostatic hyperplasia (BPH), a common disease for elder man, is accompanied by nonmalignant growth of prostate tissues, subsequently causes hypoxia and angiogenesis. Although VEGF-related angiogenesis is one of therapeutic target of prostate cancer, there is no previous study targeting angiogenesis to treat BPH. Dihydrotestosterone (DHT)-induced expressions of vascular endothelial growth factor (VEGF) in prostate epithelial RWPE-1 cells and human umbilical vascular endothelial cells (HUVECs). The conditioned media (CM) from DHT-treated RWPE-1 cells were transferred to HUVECs. Then, 6SL inhibited the angiogenesis effect of HUVECs and in vivo study from CM from DHT-treated RWPE-1 cells. These results suggest that 6SL might be a candidate for development of novel BPH drugs.
Abstract, Accepted Manuscript(in press) [Submitted on April 20, 2019, Accepted on July 13, 2019]
  Copyright © KSBMB. All rights reserved. / Powered by INFOrang Co., Ltd